Literature DB >> 30458247

Low-Normal Thyroid Function Is Associated With Advanced Fibrosis Among Adults in the United States.

Donghee Kim1, Eric R Yoo2, Andrew A Li3, Christopher T Fernandes1, Sean P Tighe1, George Cholankeril1, Bilal Hameed4, Aijaz Ahmed5.   

Abstract

The pathogenetic pathways leading to increasing prevalence of advanced fibrosis in the setting of nonalcoholic fatty liver disease (NAFLD) and resulting in higher rates of liver-related and cardiovascular morbidity and mortality in the United States are multifactorial.1 The negative health impact of "low-normal" thyroid function, which is defined as a higher level of thyroid-stimulating hormone (TSH) within the euthyroid reference range, may be comparable with overt and subclinical hypothyroidism.2-4 We reported a strong association between biopsy-proven advanced fibrosis in NAFLD with increasing TSH levels in a dose-dependent manner even within the euthyroid reference range.5 To generalize our findings across all ethnicities, we examined the association of both low-normal thyroid function and subclinical hypothyroidism with advanced fibrosis in the US general population.
Copyright © 2019 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30458247      PMCID: PMC6525074          DOI: 10.1016/j.cgh.2018.11.024

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  7 in total

1.  Setpoints and susceptibility: do small differences in thyroid function really matter?

Authors:  John P Walsh
Journal:  Clin Endocrinol (Oxf)       Date:  2011-08       Impact factor: 3.478

2.  Subclinical Hypothyroidism and Low-Normal Thyroid Function Are Associated With Nonalcoholic Steatohepatitis and Fibrosis.

Authors:  Donghee Kim; Won Kim; Sae Kyung Joo; Jeong Mo Bae; Jung Ho Kim; Aijaz Ahmed
Journal:  Clin Gastroenterol Hepatol       Date:  2017-08-18       Impact factor: 11.382

Review 3.  Low-normal thyroid function and the pathogenesis of common cardio-metabolic disorders.

Authors:  Lynnda J N van Tienhoven-Wind; Robin P F Dullaart
Journal:  Eur J Clin Invest       Date:  2015-03-09       Impact factor: 4.686

4.  Associations between the levels of thyroid hormones and lipid/lipoprotein levels: Data from National Health and Nutrition Examination Survey 2007-2012.

Authors:  Ram B Jain
Journal:  Environ Toxicol Pharmacol       Date:  2017-05-04       Impact factor: 4.860

5.  Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States.

Authors:  Donghee Kim; W Ray Kim; Hwa Jung Kim; Terry M Therneau
Journal:  Hepatology       Date:  2013-01-25       Impact factor: 17.425

Review 6.  Clinical review: A review of the clinical consequences of variation in thyroid function within the reference range.

Authors:  Peter N Taylor; Salman Razvi; Simon H Pearce; Colin M Dayan
Journal:  J Clin Endocrinol Metab       Date:  2013-07-03       Impact factor: 5.958

Review 7.  Thyroid hormone-mediated autophagy and mitochondrial turnover in NAFLD.

Authors:  Rohit Anthony Sinha; Paul M Yen
Journal:  Cell Biosci       Date:  2016-07-19       Impact factor: 7.133

  7 in total
  12 in total

1.  Low Free Triiodothyronine Is Associated with Advanced Fibrosis in Patients at High Risk for Nonalcoholic Steatohepatitis.

Authors:  Paul Manka; Lars Bechmann; Jan Best; Svenja Sydor; Lee C Claridge; Jason D Coombes; Ali Canbay; Lars Moeller; Guido Gerken; Heiner Wedemeyer; Wing-Kin Syn
Journal:  Dig Dis Sci       Date:  2019-06-03       Impact factor: 3.199

2.  Free Triiodothyronine Is Associated With Hepatic Steatosis and Liver Stiffness in Euthyroid Chinese Adults With Non-Alcoholic Fatty Liver Disease.

Authors:  Wen Guo; Pei Qin; Xiao-Na Li; Juan Wu; Jing Lu; Wen-Fang Zhu; Qing-Qing Diao; Nian-Zhen Xu; Qun Zhang
Journal:  Front Endocrinol (Lausanne)       Date:  2021-08-12       Impact factor: 5.555

3.  Severe Phenotype of Non-alcoholic Fatty Liver Disease in Pediatric Patients with Subclinical Hypothyroidism: a Retrospective Multicenter Study from Korea.

Authors:  So Yoon Choi; Dae Yong Yi; Soon Chul Kim; Ben Kang; Byung Ho Choe; Yoon Lee; Yoo Min Lee; Eun Hye Lee; Hyo Jeong Jang; You Jin Choi; Hyun Jin Kim
Journal:  J Korean Med Sci       Date:  2021-05-24       Impact factor: 2.153

Review 4.  Metabolic-associated Fatty Liver Disease (MAFLD): A Multi-systemic Disease Beyond the Liver.

Authors:  Eda Kaya; Yusuf Yilmaz
Journal:  J Clin Transl Hepatol       Date:  2021-10-19

Review 5.  Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease.

Authors:  Andrew A Li; Aijaz Ahmed; Donghee Kim
Journal:  Gut Liver       Date:  2020-03-15       Impact factor: 4.519

Review 6.  Association between Nonalcoholic Fatty Liver Disease and Endocrinopathies: Clinical Implications.

Authors:  Ana-Maria Singeap; Carol Stanciu; Laura Huiban; Cristina Maria Muzica; Tudor Cuciureanu; Irina Girleanu; Stefan Chiriac; Sebastian Zenovia; Robert Nastasa; Catalin Sfarti; Camelia Cojocariu; Anca Trifan
Journal:  Can J Gastroenterol Hepatol       Date:  2021-01-11

Review 7.  Hypothyroidism-Associated Dyslipidemia: Potential Molecular Mechanisms Leading to NAFLD.

Authors:  Maria Mavromati; François R Jornayvaz
Journal:  Int J Mol Sci       Date:  2021-11-26       Impact factor: 5.923

8.  Association Between Thyroid Hormone Levels and Advanced Liver Fibrosis in Patients with Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease.

Authors:  Jing Du; Sanbao Chai; Xin Zhao; Jianbin Sun; Xiaomei Zhang; Lili Huo
Journal:  Diabetes Metab Syndr Obes       Date:  2021-05-26       Impact factor: 3.168

9.  Association between Thyroid Function and Nonalcoholic Fatty Liver Disease in Euthyroid Type 2 Diabetes Patients.

Authors:  Bin Huang; Shengju Yang; Shandong Ye
Journal:  J Diabetes Res       Date:  2020-09-05       Impact factor: 4.011

10.  Risk of Liver Fibrosis According to TSH Levels in Euthyroid Subjects.

Authors:  Alba Martínez-Escudé; Guillem Pera; Lluís Rodríguez; Ingrid Arteaga; Carmen Expósito-Martínez; Pere Torán-Monserrat; Llorenç Caballería
Journal:  J Clin Med       Date:  2021-03-25       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.